Showing results (51-60 of 65) with videos related to
Sort By:
Pageof 7
Drugs & Aging|May 15, 2025
Age Does not Affect the Efficacy of Antibody Drug Conjugates, But is Associated with High-Grade Adverse Events in Patients with Cancer Enrolled in Early Phase Clinical TrialsAna Vaz Ferreira, Matthieu Delaye, Arnaud Pages, et al.The Lancet. Gastroenterology & Hepatology|February 3, 2022
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 studyAurelien Marabelle, Philippe A Cassier, Marwan Fakih, et al.JACC. Cardiooncology|August 16, 2021
Immune Checkpoint Inhibitor Therapy Aggravates T Cell-Driven Plaque Inflammation in AtherosclerosisKikkie Poels, Mandy M T van Leent, Celine Boutros, et al.Nature Communications|May 15, 2024
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trialsNeil H Segal, Ignacio Melero, Victor Moreno, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2019
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 StudyAurelien Marabelle, Dung T Le, Paolo A Ascierto, et al.Journal for Immunotherapy of Cancer|September 2, 2022
Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastomaAna Costa, Cécile Thirant, Amira Kramdi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2019
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid TumorsKyung Hae Jung, Patricia LoRusso, Howard Burris, et al.Journal for Immunotherapy of Cancer|April 19, 2024
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic diseaseJason J Luke, Diwakar Davar, Robert H Andtbacka, et al.Journal for Immunotherapy of Cancer|May 16, 2022
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockadeCarlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, et al.Journal for Immunotherapy of Cancer|March 17, 2016
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trialsHolbrook E Kohrt, Paul C Tumeh, Don Benson, et al.Pageof 7